These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 17356996)

  • 41. Medicare Part D: early findings on enrollment and choices for rural beneficiaries.
    McBride TD; Terry TL; Mueller KJ
    Rural Policy Brief; 2006 Apr; 10(8 (PB2006-8)):1-9. PubMed ID: 16685809
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of prescription coverage on hospital and physician costs: a case study of medicare beneficiaries with chronic obstructive pulmonary disease.
    Stuart B; Doshi JA; Briesacher B; Wrobel MV; Baysac F
    Clin Ther; 2004 Oct; 26(10):1688-99. PubMed ID: 15598486
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Understanding the Medicare Part D prescription program: partnerships for beneficiaries and health care professionals.
    De Natale ML
    Policy Polit Nurs Pract; 2007 Aug; 8(3):170-81. PubMed ID: 18178923
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of national annual variation in total patient out-of-pocket Medicare Part D stand-alone prescription drug plan costs from 2007 to 2008.
    Walberg MP; Patel RA; Amaral MM
    J Med Econ; 2008; 11(4):625-37. PubMed ID: 19450072
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Promises unfulfilled: implementation of expanded coverage for the elderly poor.
    Lamphere JA; Rosenbach ML
    Health Serv Res; 2000 Apr; 35(1 Pt 2):207-17. PubMed ID: 10778810
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans.
    Newman TV; Gabriel N; Liang Q; Drake C; El Khoudary SR; Good CB; Gellad WF; Hernandez I
    J Manag Care Spec Pharm; 2022 Feb; 28(2):266-274. PubMed ID: 35098746
    [No Abstract]   [Full Text] [Related]  

  • 47. Medicare part D and antiretroviral therapy: issues for HIV clinicians.
    Cheever LW; Vienna MR
    Top HIV Med; 2005; 13(4):122-4. PubMed ID: 16304456
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
    Polinski JM; Mohr PE; Johnson L
    Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. States' control of prescription drug spending: a heterogeneous approach.
    Morden NE; Sullivan SD
    Health Aff (Millwood); 2005; 24(4):1032-8. PubMed ID: 16012143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
    Tseng CW; Brook RH; Keeler E; Mangione CM
    JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Medicare Part D: practical practice information for healthcare providers.
    Moczygemba LR
    J Am Acad Nurse Pract; 2006 Oct; 18(10):457-62. PubMed ID: 16999710
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medicare beneficiary out-of-pocket costs: are Medicare Advantage Plans a better deal?
    Biles B; Hersch Nicholas L; Guterman Stuart S
    Issue Brief (Commonw Fund); 2006 May; 19():1-16. PubMed ID: 16733884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outpatient prescription drug utilization and expenditure patterns of noninstitutionalized aged Medicare beneficiaries.
    LaVange LM; Silverman HA
    Natl Med Care Util Expend Surv B; 1987 Apr; (12):1-43. PubMed ID: 10313516
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medicare-approved drug discount cards and renal transplant patients: how much can these cards reduce prescription costs?
    Chisholm MA; Marshall J; Smith KE; Garrett CJ; Turner JC
    Clin Transplant; 2005 Jun; 19(3):357-63. PubMed ID: 15877798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug plan design incentives among Medicare prescription drug plans.
    Huskamp HA; Keating NL; Dalton JB; Chernew ME; Newhouse JP
    Am J Manag Care; 2014 Jul; 20(7):562. PubMed ID: 25295402
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry.
    Padula WV; Ballreich J; Anderson GF
    Appl Health Econ Health Policy; 2018 Dec; 16(6):753-763. PubMed ID: 30058011
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Medicare program; establishment of the Medicare advantage program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4587-741. PubMed ID: 15678604
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predicting risk selection following major changes in Medicare.
    Pizer SD; Frakt AB; Feldman R
    Health Econ; 2008 Apr; 17(4):453-68. PubMed ID: 17557273
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Amendments to regulations regarding eligibility for a Medicare prescription drug subsidy. Interim final rule with request for comments.
    Social Security Administration
    Fed Regist; 2010 Dec; 75(249):81843-6. PubMed ID: 21261125
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 2007 costs and coverage of antiretrovirals under Medicare Part D for people with HIV/AIDS living in North Carolina.
    Sengupta S
    N C Med J; 2008; 69(1):6-13. PubMed ID: 18429558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.